TL;DR ByteDance’s drug discovery unit Anew Labs presented its first AI-designed therapy at a major immunology conference in Boston, showing a generative-AI-designed small molecule targeting IL-17, a protein-protein interaction long considered undruggable. The unit also published AnewOmni, a generative framework trained on 5 million biomolecular complexes that claims to be the first to design functional molecules across all scales. ByteDance has entered the AI drug discovery race alongside Isomorphic Labs, Anthropic, and Insilico Medicine. The company that built TikTok’s recommendation algorithm, the system that predicts with unsettling accuracy what a person wants to watch next, is now using a related class of AI to predict how molecules will behave inside a human body.…